1.
Bioorg Med Chem Lett
; 25(17): 3447-50, 2015 Sep 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26206503
RESUMO
We tested cytotoxicity of aminoferrocene-based prodrugs towards human androgen-responsive and unresponsive prostate cancer cell lines LNCaP and DU-145 correspondingly. Two prodrugs were selected, which are both activated at elevated concentrations of ROS with generation of quinone methide (antioxidant system inhibitor) and iron-containing compounds (N-benzylaminoferrocene (prodrug 1) and Fe salts (2)). We observed that only prodrug 1 is active against the selected prostate cancer cells (IC50=11-27 µM) and its activity correlates with the high cell-membrane permeability and increased production of intracellular ROS.